|
1）大槻 眞，藤野善久．慢性膵炎登録患者の予後および死因に関する検討．厚生労働省難治性疾患克服研究事業難治性膵疾患に関する調査研究平成18年度総括・分担研究報告書．2007; 98-102
|
|
|
|
|
2）笹平直樹，中井陽介，水野 卓，他．膵石症-膵発癌を視野に入れた長期予後: 膵発癌関連因子．肝胆膵．2009; 58: 531-9
|
|
|
|
|
3）Malka D, Hammel P, Maire F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002; 51(6): 849-52
|
|
|
|
|
4）Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011；40(3): 352-8
|
|
|
|
|
|
5）Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012 ; 22(1): 21-30
|
|
|
|
|
|
6）Mercer LK, Davies R, Galloway JB, et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford). 2013; 52(1): 91-8
|
|
|
|
|
|
7）Kamisawa T, Tsuruta K, Okamoto A, et al. Frequent and significant K-ras mutation in the pancreas, the bile duct, and the gallbladder in autoimmune pancreatitis. Pancreas. 2009; 38(8): 890-5
|
|
|
|
|
|
8）Moo-Young TA, Larson JW, Belt BA, et al. Tumor-derived TGF-[beta]mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother. 2009; 32(1): 12-21
|
|
|
|
|
|
9）Granville CA, Memmott RM, Balogh A, et al. A central role for Fozp3+ regulatory T cells in K-ras-driven lung tumorigenesis. PLoS ONE. 2009; 4: e5061
|
|
|
|
|
|
10）Gupta R, Khosroshahi A, Shinagare S, et al. Does autoimmune pancreatitis increase the risk of pancreatic carcinoma? a retrospective analysis of pancreatic resections. Pancreas. 2013; 42(3): 506-10
|
|
|
|
|
|
11）Khalid A, Dewitt J, Ohori NP, et al. EUS-FNA mutational analysis in differentiating autoimmune pancreatitis and pancreatic cancer. Pancreatology. 2011; 11(5): 482-6
|
|
|
|
|
|
12）Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009; 58(11): 1504-7
|
|
|
|
|
|
13）平野賢二，水野 卓，多田 稔，他．原発性硬化性胆管炎と胆道癌．外科．2012; 74: 1190-5
|
|
|
|
|
|
14）Kawakubo K, Tada M, Isayama H, et al. Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011; 60(9): 1249-53
|
|
|
|
|
|
15）Ury HK, Wiggins AD. Another shortcut method for calculating the confidence interval of a Poisson variable (or of a standardized mortality ratio). Am J Epidemiol. 1985; 122(1): 197-8
|
|
|
|
|
|
16）Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 2013; 104(1): 9-14
|
|
|
|
|
|
17）Kamisawa T, Horiguchi S, Hayashi Y, et al. K-ras mutation in the major duodenal papilla and gastric and colonic mucosa in patients with autoimmune pancreatitis. J Gastroenterol. 2010; 45(7): 771-8
|
|
|
|
|
|
18）Yamamoto M, Takahashi H, Tabeya T, et al. Risk of malignancies in IgG4-related disease. Mod Rheumatol. 2012; 22(3): 414-8
|
|
|
|
|
|
19）Shiokawa M, Kodama Y, Yoshimura K, et al. Risk of cancer in patients with autoimmune pancreatitis. Am J Gastroenterol. 2013; 108(4): 610-7
|
|
|
|
|
|
20）Hirano K, Tada M, Sasahira N, et al. Incidence of malignancies in patients with IgG4 related disease. Internal Medicine. (in press)
|
|
|
|
|